Literature DB >> 11494912

[Clinical value of urinary pyridinium crosslinks as osteoporosis markers: evaluation of a population survey of vertebral osteoporosis].

A Behre1, J Janott, M Pfohl, H Schatz, A Pfeiffer.   

Abstract

BACKGROUND: The diagnostic value of biochemical parameters of bone turnover for the diagnosis of osteoporosis is open to discussion. We investigated whether the determination of crosslinks, bone type I collagen degradation products, correctly identifies osteoporotic subjects. PATIENTS AND
METHOD: In a sample of 370 individuals recruited at random within a population survey of vertebral osteoporosis, urinary concentration of total pyridinoline and desoxypyridinoline were determined by HPLC. Standardized lateral X-rays of the thoracic and lumbar spine were taken and evaluated morphometrically using the method described by Eastell-Melton.
RESULTS: Crosslink excretion was significantly higher in female but not in male individuals with vertebral deformities as defined by Eastell. The specificity of these biochemical parameters with regard to radiological osteoporotic alterations was 76-81%, but the sensitivity was 32.4-42.9% only.
CONCLUSION: Pyridinoline and desoxypyridinoline reflect the process of bone degradation which leads to vertebral deformity. Crosslinks are specific markers of bone resorption and provide a valid parameter in the diagnosis of osteoporosis. The low sensitivity indicates that the measurement of pyridinoline and desoxypyridinoline is less suitable for screening purposes, but may be useful in confirming presence or extent of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494912     DOI: 10.1007/pl00002219

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  1 in total

Review 1.  [Pain management in osteoporosis].

Authors:  L Heuchemer; D Emmert; T Bender; T Rasche; M Marinova; A Kasapovic; R Conrad; M Mücke
Journal:  Orthopade       Date:  2020-04       Impact factor: 1.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.